[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551317":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Centre Paul Strauss","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Intraoral PBM",null,[12],"Device: Photobiomodulation session - intraoral",{"label":14,"type":6,"description":10,"interventionNames":15},"Transcutaneous PBM",[16],"Device: Photobiomodulation session - transcutaneous",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DEVICE","Photobiomodulation session - intraoral","use of CareMin650TM lightbox(NeoMedLight) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose",[9],{"type":19,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Photobiomodulation session - transcutaneous","use of ATP38® phototherapy device (Swiss Bio Inov Europe) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose",[14],[28],{"name":29,"affiliation":30,"role":31},"Jordan EBER, MD","Institut de cancérologie Strasbourg Europe","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Manon VOEGELIN","CONTACT","VOEGELIN","+33","promotion-rc@icans.eu",[40],{"facility":30,"status":10,"city":41,"state":10,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Strasbourg","67033","France","FR",{"type":46,"coordinates":47},"Point",[48,49],7.74553,48.58392,{"lat":49,"lon":48},[52],{"name":34,"role":35,"phone":53,"phoneExt":37,"email":38},"368339523",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100551317","evaluation-of-two-methods-of-administration-of-photobiomodulation-in-the-context-of-the-prevention-and-treatment-of-mucositis-induced-by-radiotherapy-during-the-treatment-of-head-and-neck-cancers-100551317",false,"NCT06458517","Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers","Pilot Observational Study of Transcutaneous and Intraoral Photobiomodulation in the Prevention and Treatment of Radiomucositis in Head and Neck Cancers Treated by Radiotherapy - RADIO-PBM Trial","RADIO-PBM","Inclusion Criteria:\n\n* Adult patient (18 years old and older);\n* Patients with oral cavity or oropharynx cancer treated with radiotherapy or chemo-radiotherapy;\n* Karnofsky Performance Status \\> 60%;\n* Able to understand French;\n* With signed informed consent;\n* Affiliated to French Health Security Insurance\n\nExclusion Criteria:\n\n* Allergy to polyurethanes;\n* Head and Neck tumors that are localized to other sites than oral cavity or oropharynx\n* Previous irradiation of Head and Neck (whatever the time lapse between the two irradiations)\n* Pregnant and breastfeeding woman;\n* Patients with pacemaker device\n* Epileptic patients;\n* Concomitant treatment or treatment within the 7 days before inclusion with one of several drugs from the following list: fluoroquinolones, cycline, methotrexate, auranofin\n* Patients with ophthalmic diseases (such as maculopathy, retinopathy, glaucoma and cataract, retinal damage)\n* Patients under judicial protection","ALL","18 Years",{"count":67,"type":68},60,"ESTIMATED","INTERVENTIONAL",[71],"NA","The aim of this feasibility, prospective, single-center trial is to compare an intra-oral Photobiomodulation (PBM) via the Caremin650TM device (NeoMedLight) and a transcutaneous PBM via the ATP 38® device (Swiss Bio Innov) in patients treated with radiotherapy or chemoradiotherapy for cancer of the oropharynx or oral cavity. PBM session will be carried out first at the rate of two sessions per week for preventive purposes, and then, in case of occurence of grade 1 mucositis, three sessions per week with curative purpose.",[74],"Head and Neck Neoplasms",[76,77,78,79,80],"Radiotherapy","Chemotherapy","Photobiomodulation therapy","Low-level laser therapy","Oral mucositis","NOT_YET_RECRUITING","2026-06-04",{"date":84,"type":85},"2026-06-05","ACTUAL",{"date":87,"type":68},"2026-06-15",{"date":89,"type":68},"2029-11-15",{"name":5,"class":6},1]